Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient
- 1Department of Neurology, The Second Affiliated Hospital of Harbin Medical University
Abstract
Introduction: Efgartigimod, an antagonist of the neonatal Fc receptor, has demonstrated efficacy in generalized myasthenia gravis, but evidence from routine clinical practice remains limited, and its immunological effects beyond immunoglobulin G reduction are incompletely understood.
Methods: We retrospectively evaluated the 12-week effectiveness and safety of Efgartigimod in 21 patients with acetylcholine receptor antibody-positive generalized myasthenia gravis. Outcomes included changes in Myasthenia Gravis Activities of Daily Living scores, response rates defined by reductions of ≥2 and ≥5 points, achievement of minimal symptom expression, changes in prednisone dosage, and adverse events. To explore potential longer-term immune changes, paired peripheral blood mononuclear cell samples obtained from one patient at baseline and after 6 months of repeated treatment were analyzed using single-cell RNA sequencing and T- and B-cell receptor repertoire sequencing.
Results: The median MG-ADL score decreased from 7.0 (IQR, 6.0–8.0) at baseline to 1.0 (IQR, 1.0–1.5) at week 12. After the first and second treatment cycles, 85.7 and 94.7% of patients achieved CMI, respectively, while 57.1 and 84.2% achieved ≥5-point reductions. At week 12, 73.7% of patients achieved MSE. Treatment was generally well tolerated, with two mild adverse events and no serious adverse events. Exploratory longitudinal profiling in one patient identified reduced myeloid inflammatory activity and antigen-presentation signatures, attenuated predicted inflammatory intercellular communication, and a more dispersed pattern of T- and B-cell clonal expansion after prolonged treatment.
Conclusion: The clinical cohort findings support the effectiveness and favorable safety profile of Efgartigimod in routine practice. The exploratory single-cell and immune repertoire analyses from one patient provide preliminary insights into potential immunological changes beyond IgG reduction and require validation in larger cohorts.
Related
- Real-world efficacy and safety of efgartigimod in patients with autoimmune encephalitis: a single-center retrospective analysiss
- Alternate-Day Versus Consecutive-Day Anti-T Lymphocyte Globulin Induction in First Living-Donor Kidney Transplant Recipients at Low Immunological Risk: A Retrospective Cohort Study
- Toward personalized and longitudinal antibiograms--a proof-of-concept for in vivo assessments of immunological-antibiotic-bacterial interactions
- Longitudinal real-time PCR monitoring of CMV DNAemia and renal function in living-donor kidney transplant recipients with low immunological risk.
- Pre-TAS Evaluation of mass drug administration effectiveness on lymphatic filariasis elimination and study of Immunological response in elephantiasis patients in Osun State, Nigeria
BibTeX
@article{tian2026realworld,
title = {{Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient}},
author = {Liting Tian and Lanxin Zhang and Jingnan Jin and Xia Wang and Zihong Chen and Lukuan Qiao and Qingling Guo and Yan Li and Jiayi Zhang and Yufan Zhao and Lihua Wang and Lei Li and Jianjian Wang},
journal = {Frontiers in Neurology},
year = {2026},
month = oct,
doi = {10.3389/fneur.2026.1980412},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1980412/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient
AU - Liting Tian
AU - Lanxin Zhang
AU - Jingnan Jin
AU - Xia Wang
AU - Zihong Chen
AU - Lukuan Qiao
AU - Qingling Guo
AU - Yan Li
AU - Jiayi Zhang
AU - Yufan Zhao
AU - Lihua Wang
AU - Lei Li
AU - Jianjian Wang
PY - 2026
DA - 2026/10/19
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1980412
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1980412/full
AB - Introduction: Efgartigimod, an antagonist of the neonatal Fc receptor, has demonstrated efficacy in generalized myasthenia gravis, but evidence from routine clinical practice remains limited, and its immunological effects beyond immunoglobulin G reduction are incompletely understood. Methods: We retrospectively evaluated the 12-week effectiveness and safety of Efgartigimod in 21 patients with acetylcholine receptor antibody-positive generalized myasthenia gravis. Outcomes included changes in Myasthenia Gravis Activities of Daily Living scores, response rates defined by reductions of ≥2 and ≥5 points, achievement of minimal symptom expression, changes in prednisone dosage, and adverse events. To explore potential longer-term immune changes, paired peripheral blood mononuclear cell samples obtained from one patient at baseline and after 6 months of repeated treatment were analyzed using single-cell RNA sequencing and T- and B-cell receptor repertoire sequencing. Results: The median MG-ADL score decreased from 7.0 (IQR, 6.0–8.0) at baseline to 1.0 (IQR, 1.0–1.5) at week 12. After the first and second treatment cycles, 85.7 and 94.7% of patients achieved CMI, respectively, while 57.1 and 84.2% achieved ≥5-point reductions. At week 12, 73.7% of patients achieved MSE. Treatment was generally well tolerated, with two mild adverse events and no serious adverse events. Exploratory longitudinal profiling in one patient identified reduced myeloid inflammatory activity and antigen-presentation signatures, attenuated predicted inflammatory intercellular communication, and a more dispersed pattern of T- and B-cell clonal expansion after prolonged treatment. Conclusion: The clinical cohort findings support the effectiveness and favorable safety profile of Efgartigimod in routine practice. The exploratory single-cell and immune repertoire analyses from one patient provide preliminary insights into potential immunological changes beyond IgG reduction and require validation in larger cohorts.
SN - 1664-2295
ER -